GetTopicDetailResponse(id=f787895480d, topicName=血管內皮生長因子受體, introduction=血管內皮生長因子受體, content=null, image=null, comments=2, allHits=800, url=https://h5.medsci.cn/topic?id=89548, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=51543, tagList=[TagDto(tagId=51543, tagName=血管內皮生長因子受體)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2253275, encodeId=b94922532e5e2, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#轉移性腎細胞癌#</a> <a href='/topic/show?id=f787895480d' target=_blank style='color:#2F92EE;'>#血管內皮生長因子受體#</a> <a href='/topic/show?id=fb281245284d' target=_blank style='color:#2F92EE;'>#免疫檢查點阻斷劑#</a>, objectTitle=Eur Urol Oncol：轉移性腎細胞癌患者接受不同一線治療方案后的無治療生存期比較分析, objectType=article, longId=864513, objectId=143186451378, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720172869669_92910.png, objectUrl=/article/show_article.do?id=143186451378, replyNumber=0, likeNumber=25, createdTime=2025-02-24, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=143186451378, moduleTitle=Eur Urol Oncol：轉移性腎細胞癌患者接受不同一線治療方案后的無治療生存期比較分析, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=143186451378)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1812268, encodeId=3c2a18122684b, content=<a href='/topic/show?id=f787895480d' target=_blank style='color:#2F92EE;'>#血管內皮生長因子受體#</a>, objectTitle=2016EAU指南——血管內皮生長因子受體抵抗的腎臟透明細胞癌的靶向治療發(fā)布, objectType=article, longId=79519, objectId=e5e8e951937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5e8e951937, replyNumber=0, likeNumber=52, createdTime=2017-04-14, rootId=0, userName=仁心濟世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5e8e951937, moduleTitle=2016EAU指南——血管內皮生長因子受體抵抗的腎臟透明細胞癌的靶向治療發(fā)布, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e5e8e951937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1812269, encodeId=e0861812269cc, content=<a href='/topic/show?id=f787895480d' target=_blank style='color:#2F92EE;'>#血管內皮生長因子受體#</a>, objectTitle=Ophthalmologica：糖尿病黃斑水腫患者的眼房水中可溶性血管內皮生長因子受體(sVEGFR)和炎癥因子的水平顯著高于非糖尿病人！, objectType=article, longId=100470, objectId=3fb01004e068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb01004e068, replyNumber=0, likeNumber=77, createdTime=2017-08-16, rootId=0, userName=仁心濟世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb01004e068, moduleTitle=Ophthalmologica：糖尿病黃斑水腫患者的眼房水中可溶性血管內皮生長因子受體(sVEGFR)和炎癥因子的水平顯著高于非糖尿病人！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3fb01004e068)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
